Clinical trials for rare diseases can be challenging to design, meet targeted enrollment, and obtain sufficient evidence of efficacy for FDA labeling of new drugs to treat these orphan diseases. Autoimmune inner ear disease, and related diseases of immune mediated hearing loss are yet to be classified orphan diseases. In this chapter, we have addressed some of the unique challenges in designing clinical trials for Autoimmune Inner Ear Disease, Sudden Sensorineural Hearing Loss, Meniere's Disease and Autoinflammatory Diseases.
CITATION STYLE
Vambutas, A., & Lesser, M. L. (2018). Implementation and outcomes of clinical trials in immune-mediated hearing loss and other rare diseases. In Inflammatory Mechanisms in Mediating Hearing Loss (pp. 211–223). Springer International Publishing. https://doi.org/10.1007/978-3-319-92507-3_11
Mendeley helps you to discover research relevant for your work.